©TheCanadian Journal ofUrology™: International Supplement, April 2014
20
Traditional androgen ablation approaches to advancedprostate cancer: new insights
19.CooperbergM, Broering J, Carroll PR. Time trends and local
variation in primary treatment of localized prostate cancer.
J ClinOncol
2010;28(7):1117-1123.
20.Cooperberg MR, Hinotsu S, Namiki M et al. Trans-pacific
variation inoutcomes formen treatedwithprimaryandrogen
deprivation therapy for localized prostate cancer. Annual
ProstateCancer FoundationRetreat 2012.
21.ShelleyMD, Kumar S, Wilt TJ et al. A systematic review and
meta-analysis of randomised trials of neo-adjuvant hormone
therapy for localisedand locallyadvancedprostatecarcinoma.
CancerTreatRev
2009;35(1):9-17.
22.TrumpDL,MessingEM,CrawfordEDet al. Immediateversus
deferredandrogendeprivation treatment inpatientswithnode-
positiveprostate cancer after radical prostatectomyandpelvic
lymphadenectomy.
LancetOncol
2006;7(6):472-479.
23.TammelaTL, IversenP, Johansson J-Eetal.Bicalutamide150mg
inadditiontostandardcareforpatientswithearlynon-metastatic
prostate cancerupdated results from theScandinavianprostate
cancerperiodgroup-6studyafteramedian follow-upperiodof
7.1years.
Scand JUrolNephrol
2006;40(6):441-452.
24.Tangen CM, Swanson GP, Crawford ED et al. Adjuvant
androgendeprivation forhigh-riskprostatecancerafterradical
prostatectomy: SWOG S9921 study.
J Clin Oncol
2011;29(15):
2040-2045.
25.Bolla M, Gonzalez D, Warde P et al. Improved survival in
patients with locally advanced prostate cancer treated with
radiotherapy andgoserelin.
NEngl JMed
1997;337(5):295-300.
26.BollaM, vanTienhovenG,Warde P et al. External irradiation
with orwithout long-term androgen suppression for prostate
cancerwithhighmetastatic risk: 10-year results of anEORTC
randomised study.
LancetOncol
2010;11(11):1066-1073.
27. JonesCU,HuntD,McGowanDGetal.Radiotherapyandshort-
termandrogendeprivation for localizedprostatecancer.
NEngl
JMed
2011;365(2):107-118.
28.D’AmicoAV, Manola J, LoffredoM et al. 6-month androgen
suppression plus radiation therapy vs radiation therapy
alone for patients with clinically localized prostate cancer:
a randomized controlled trial.
JAMA
2004;292(7):821-827.
29.Bolla M, de Reijke TM, van Tienhoven G et al. Duration of
androgen suppression in the treatment of prostate cancer.
NEngl JMed
2009;360(24):2516-2527.
30.LawtonCA,DeSilvioM,RoachMetal.Anupdateof thephase
III trial comparingwholepelvic toprostate only radiotherapy
and neoadjuvant to adjuvant total androgen suppression:
updatedanalysisofRTOG94-13,withemphasisonunexpected
hormone/radiation interactions.
Int J Radiat Oncol Biol Phys
2007;69(3):646-655.
31.Klotz LH, Whitmore WF Jr, Herr HW et al. Intermittent
endocrine therapy for advanced prostate cancer.
Cancer
1986;58(11):2546-2550.
32.Bruchovsky N, To M, Rennie PS et al. Effects of androgen
withdrawal on the stem cell composition of the Shionogi
carcinoma.
CancerRes
1990;50(8):2275-2282.
33.Akakura K, Bruchovsky N, Goldenberg SL et al. Effects of
intermittent androgen suppression on androgen-dependent
tumors.Apoptosisandserumprostate-specificantigen.
Cancer
1993;71(9):2782-2790.
34.SatoN,GleaveME,BruchovskyNet al. Intermittent androgen
suppression delays progression to androgen-independent
regulation of prostate-specific antigen gene in the LNCaP
prostate tumour model.
J Steroid BiochemMol Biol
1996;58(2):
139-146.
35.Crook JM, O’Callaghan CJ, Duncan G et al. Intermittent
androgen suppression for risingPSA level after radiotherapy.
NEngl JMed
2012;367(10):895-903.
36.HussainM, Thompson IM Jr, VogelzangNJ et al. Intermittent
versus continuous androgen deprivation in prostate cancer.
NEngl JMed
2013;368(14):1314-1325.
37.Blumberg JM,KwonEO,CheethamTCetal.Earlydevelopment
of castrate resistance varies with different dosing regimens of
luteinizing hormone releasing hormone agonist in primary
hormonal therapyforprostatecancer.
Urology
2011;77(2):412-416.
38.Schally AV, Redding TW, Comaru-Schally AM. Inhibition of
prostate tumors by agonistic and antagonistic analogs of LH-
RH.
Prostate
1983;4(6):545-552.
39.SchröderF,CrawfordED,AxcronaKetal.Androgendeprivation
therapy: past, present and future.
BJUI
2012;109(Suppl 6):1-12.
40.LabrieF,BelangerA,DupontAetal.Combined treatmentwith
LHRHagonist andpureantiandrogen inadvanced carcinoma
of prostate.
Lancet
1984;2(8411):1090.
41.KlotzL,Boccon-GibodL,ShoreNDetal.Theefficacyandsafety
ofdegarelix:a12-month, comparative, randomized,open-label,
parallel-groupphase III study inpatientswithprostatecancer.
Br JUrol
2008;102(11):1531-1538.
42.OefeleinMG, CornumR. Failure to achieve castrate levels of
testosterone during luteinizing hormone releasing hormone
agonist therapy: thecase formonitoringserum testosteroneand
a treatmentdecisionalgorithm.
JUrol
2000;164(3Pt 1):726-729.
43.Tombal B, Berges R. How good do current LHRH agonists
control testosterone? Can this be improved with Eligard®?
EurUrol Suppl
2005;4(8):30-36.
44.CrawfordED, RoveKO. Incomplete testosterone suppression
inprostate cancer.
NEngl JMed
2010;363(20):1976.
45.RoveKO,DebruyneFM,DjavanBet al.Roleof testosterone in
managingadvancedprostatecancer.
Urology
2012;80(4):754-762.
46.Tombal B, BergesR. Optimal control of testosterone: a clinical
case-basedapproachofmodernandrogen-deprivation therapy.
EurUrol Suppl
2008;7:15-21.
47.Novara G, Galfano A, Secco S et al. Impact of surgical and
medicalcastrationonserum testosterone level inprostatecancer
patients.
Urol Int
2009;82(3):249-255.
48.Crawford ED, Rove KO, BrawerMK, et al. Determination of
clinical characteristics for men onADT as related to baseline
serum testosteronevalues [abstract 161];AmericanUrological
AssociationAnnualMeeting;May14–19,2011;Washington,DC.
49.MoroteJ,OrsolaA,PlanasJetal.Redefiningclinicallysignificant
castration levels in patients with prostate cancer receiving
continuousandrogendeprivationtherapy.
JUrol
2007;178(4Pt1):
1290-1295.
50.PerachinoM, CavalliV, Bravi F. Testosterone levels inpatients
with metastatic prostate cancer treated with luteinizing
hormone-releasinghormone therapy: prognostic significance?
BJU Int
2010;105(5):648-651.
51.Pickles T, Hamm J, Morris WJ et al. Incomplete testosterone
suppression with luteinizing hormone-releasing hormone
agonists:does ithappenanddoes itmatter?
BJU Int
2012;110(11
Pt B):E500-E507.
52.Keating NL, O’Malley AJ, Freedland SJ et al. Diabetes and
cardiovascular disease during androgendeprivation therapy:
observational study of veterans with prostate cancer.
J Natl
Cancer Inst
2010;102(1):39-46.
53.Greenspan SL, Coates P, Sereika SM et al. Bone loss after
initiation of androgen deprivation therapy in patients with
prostate cancer.
JClinEndocrinolMetab
2005;90(12):6410-6417.
54.LevineG, D’AmicoAV, Berger P et al. Androgen-deprivation
therapy in prostate cancer and cardiovascular risk: a science
advisory from the American Heart Association, American
CancerSociety,andAmericanUrologicalAssociation:endorsed
by the American Society for Radiation Oncology.
Circulation
2010;121(6):833-840.
55.Update to ongoing safety review of GnRH agonists and
notification to manufacturers of GnRH agonists to add new
safety information to labeling regarding increased risk of
diabetesandcertaincardiovasculardiseases.U.S.FoodandDrug
Administration2010.Availableat:http://www.fda.gov/Drugs/
DrugSafety/ucm229986.htm, accessedSeptember 22, 2013.
